[Impact of Her2 and BRCA1/2 status in high-dose chemotherapy and autologous stem cells transplantation in the treatment of breast cancer: The Institut Paoli Calmettes' experience].

Laurys Boudin,Christian Chabannon,Patrick Sfumato,Renaud Sabatier,François Bertucci,Carole Tarpin,Magali Provansal,Gilles Houvenaeghel,Eric Lambaudie,Agnès Tallet,Michel Resbeut,Emmanuelle Charafe Jauffret,Boris Calmels,Claude Lemarie,Jean-Marie Boher,Jean Marc Extra,Patrice Viens,Anthony Gonçalves

[Impact of Her2 and BRCA1/2 status in high-dose chemotherapy and autologous stem cells transplantation in the treatment of breast cancer: The Institut Paoli Calmettes' experience].

2017

Laurys Boudin
Christian Chabannon
Patrick Sfumato
Renaud Sabatier
François Bertucci
Carole Tarpin
Magali Provansal
Gilles Houvenaeghel
Eric Lambaudie
Agnès Tallet
Michel Resbeut
Emmanuelle Charafe Jauffret
Boris Calmels
Claude Lemarie
Jean-Marie Boher
Jean Marc Extra
Patrice Viens
Anthony Gonçalves

Studies evaluating chemotherapy high dose chemotherapy with autologous haematopoietic stem cell transplantation (HDC-ACSH) in the treatment of metastatic (MBC), locally advanced (LABC) and inflammatory (IBC) breast cancer have in common lack of biomarker information, in particular the HER2 status.

Keywords:

Haematopoiesis
Transplantation
Internal medicine
Breast cancer
Oncology
Stem cell
Chemotherapy
Biomarker (medicine)
Medicine

Correction
Cite
Save
Machine Reading By IdeaReader

References

Citations